A. Zukiwski

发表

AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins

P. Dent, E. Damonte, M. Tuñón, 2016, Journal of clinical & cellular immunology.

AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication

P. Dent, C. García, Federico Giovannoni, 2016, Journal of cellular physiology.

Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization

S. Wallace, G. Mavligit, L. Lamki, 1991, Cancer.

A phase I study of escalating interferon alpha-2a combined with 5-fluorouracil and leucovorin in patients with gastrointestinal malignancies.

G. Batist, A. Langleben, M. Trudeau, 1993, Acta oncologica.

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.

J. Murray, D. Podoloff, R. Benjamin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen.

J. Murray, R. Benjamin, S. Legha, 1990, Cancer research.

Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function

B. Shuch, C. Chen, Dasheng Wang, 2016, Oncotarget.

Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy

J. Murray, C. Balch, M. Talpaz, 1991, Cancer Immunology, Immunotherapy.

A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer

G. Batist, A. Langleben, M. Trudeau, 2004, Cancer Chemotherapy and Pharmacology.

Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center

J. Murray, C. Balch, R. Benjamin, 1989 .

Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.

G. Hortobagyi, S. Singletary, A. Buzdar, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.

J. Murray, K. Mujoo, M. Rosenblum, 1990, Journal of biological response modifiers.

Increased incidence of hypersensitivity to iodine‐containing radiographic contrast media after interleukin‐2 administration

J. Gutterman, S. Wallace, G. Mavligit, 1990, Cancer.

The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions

S. Gilch, D. Abdelaziz, S. Proniuk, 2017, Scientific Reports.

Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.

R. Amato, A. Sella, L. Finn, 1994, Cancer biotherapy.

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.

C. Logothetis, R. Amato, S. Tu, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rifampin-resistant meningococcal infection in a patient given rifampin chemoprophylaxis.

G. Bodey, K. Rolston, A. Zukiwski, 1988, American journal of infection control.

Severe, symptomatic, dose‐limiting hypophosphatemia induced by hepatic arterial infusion of recombinant tumor necrosis factor in patients with liver metastases

A. Giglio, G. Mavligit, A. Zukiwski, 1991, Cancer.

Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.

C. Charnsangavej, S. Wallace, J. Gutterman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trans-ungual Delivery of AR-12, a Novel Antifungal Drug

S. N. Murthy, C. Rappleye, H. Shivakumar, 2017, AAPS PharmSciTech.

Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort

S. Fuqua, J. Bonneterre, J. Bosq, 2016, ESMO Open.

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

C. Logothetis, R. Amato, A. Sella, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma

C. Logothetis, R. Amato, J. Ellerhorst, 1994 .

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

A. Italiano, J. Bonneterre, M. Campone, 2018, PloS one.

Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.

B. Monk, J. Graham, C. Clarke, 2015, Gynecologic oncology.

A single-dose PK study of onapristone including the effect of food on absorption

A. Patat, D. Chassard, A. Bexon, 2015, Cancer Chemotherapy and Pharmacology.

A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.

C. Shapiro, M. Garrett, T. Yap, 2013 .

5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen.

C. Logothetis, R. Amato, G. Recondo, 1994, Anticancer research.

Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer.

A Sella, B. Aggarwal, B B Aggarwal, 1995, Cancer biotherapy.

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.

R. Amato, E. Jones, J. Ellerhorst, 1994, The Journal of urology.

Abstract 4523: Population pharmacokinetic (PPK) modeling of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers

A. Italiano, J. Bonneterre, M. Campone, 2015 .

Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study.

A. Italiano, J. Bonneterre, M. Campone, 2015 .

Abstract 3471: Comparative assessment of in vitro activity and aactivated progesterone receptor (APR) biomarker predictivity for multiple antiprogestins

J. Bosq, G. Serin, C. Alleaume, 2015 .

Identification of the activated form of the progesterone receptor (PR) in breast cancer (BC).

S. Fuqua, J. Bonneterre, J. Bosq, 2013 .

Determination of the activated form of the progesterone receptor (PR) in endometrial cancer (EC).

B. Monk, C. Clarke, J. Bosq, 2013 .

Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

C. Brennan, O. Basturk, P. Kingham, 2020, The oncologist.

Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC).

S. Fuqua, J. Bonneterre, J. Bosq, 2013 .